Articles tagged "HLA antibodies"

2019 American Transplant Congress
Vaccination And Allosensitization In Solid Organ Transplant Candidates
L. Lourenco¹, K. B. Bain², L. Bowman³, D. C. Brennan⁴, G. A. Ewald⁵, R. R. Hachem⁶
¹Pharmacy, University of Chicago Medicine, Chicago, IL, ²Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ³Pharmacy, Tampa General Hospital, Tampa, FL, ⁴Internal Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, ⁵Heart Failure and Heart Transplantation, Washington University School of Medicine, St. Louis, MO, ⁶Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO
*Purpose: Clinical practice guidelines recommend vaccinating patients awaiting solid organ transplantation (SOT) against vaccine-preventable infections, but there is little evidence to suggest that vaccination reduces…
2019 American Transplant Congress
Anti-HLA Antibodies Are Associated with Deterioration in Long-Term Renal Function Independently of Donor Specificity
T. Mueller¹, P. Cippa², R. van Breemen¹, S. von Moos¹
¹Universityspital Zurich, Zurich, Switzerland, ²Ospedale Regionale di Lugano Civico, Lugano, Switzerland
*Purpose: Donor-specific antibodies (DSA) negatively impact graft survival, the clinical relevance of non-donor-specific anti-HLA antibodies (NDSA) is unclear. Hence, the purpose of our study is…
2019 American Transplant Congress
The Effect Of Exclusive Virtual Crossmatch To Allocate Deceased Donor Kidney Transplant On Cold Ischemia Time And Acute Rejection
E. Abuhelaiqa¹, M. Alkadi¹, S. Thappy¹, S. Saleh², J. Mahmoud³, M. Jarman³, O. Fituri¹, M. Elkhalifa⁴, J. Wadström³, H. Al-Malki¹
¹Medicine-Nephrology, Hamad Medical Corporation, Doha, Qatar, ²Histocompatibility & Immunogenetics Laboratory,, Hamad Medical Corporation, Doha, Qatar, ³Surgery-Transplant, Hamad Medical Corporation, Doha, Qatar, ⁴Histocompatibility & Immunogenetics Laboratory, Hamad Medical Corporation, Doha, Qatar
*Purpose: Virtual crossmatch (VXM) using Luminex single antigen bead has significantly improved prediction of an actual negative crossmatch. A negative crossmatch is typically required for…
2019 American Transplant Congress
Donor-Recipient HLA Mismatched Peptides Calculated by PIRCHE Algorithm Associate with De Novo Donor-Specific Cellular and Humoral Alloreactivity and Predicts Inferior Graft Outcome
M. Meneghini¹, E. Crespo², M. Niemann³, A. Torija², E. Melilli⁴, M. Jarque², N. Montero⁴, J. Cruzado¹, J. Grinyo¹, O. Bestard¹
¹Kidney Transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ²Experimental Nephrology Laboratory, IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ³PIRCHE AG, Berlin, Germany, ⁴Kidney Transplantation Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat. Barcelona, Spain
*Purpose: PIRCHE-II algorithm predicts mismatched donor-derived HLA peptides number presented on recipient HLAclass-II molecules to recipient T-cells (indirect pathway of allorecognition) and has been associated…
2019 American Transplant Congress
Perioperative Blood Transfusion and Risk for Post-Transplant Sensitization and Rejection
A. Chung¹, M. Kleman¹, T. Pesavento¹, M. Abdel-Rasoul², R. Daloul¹
¹Internal Medicine, Division of Nephrology, The Ohio State University, Columbus, OH, ²Center for Biostatistics and Bioinformatics, The Ohio State University, Columbus, OH
*Purpose: Pre-transplant blood transfusion is a well-established risk factor for sensitization to human leukocyte antigens (HLA). HLA sensitization is associated with increased wait-list time, risk…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…
2019 American Transplant Congress
Presence of DSA Class 2 is Associated with Fibrosis Progression after OLT
M. Sterneck¹, B. Sultani², M. Rodriguez Lago³, E. Grabhorn⁴, A. Briem-Richter⁴, U. Herden⁵, L. Fischer⁵
¹University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Depatment of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁴Department of Paediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁵Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: For decades, donor-specific antibodies (DSA) have been thought not to be clinically relevant in orthotopic liver transplantation (OLT). However, recent studies have shown a…
2019 American Transplant Congress
Global Analysis of Fc-gamma Receptors Binding Capacity of Human Leukocyte Antigen Donor Specific Antibody
E. S. Woodle, A. Girnita
University of Cincinnati Academic Health Center, Cincinnati, OH
*Purpose: Functional assessment of anti-HLA antibodies has historically been limited to complement-binding assays. However, antibodies are capable of inducing injury by complement-independent mechanisms, including Fc-gamma…
2019 American Transplant Congress
Yellow Fever and Renal Transplantation: Influence of Vaccination and Infection on the Emergence of Antibody-Mediated Rejection
M. V. Sousa¹, R. L. Zollner², R. S. Stucchi³, I. F. Boin⁴, E. C. Ataide⁴, M. Mazzali¹
¹Department of Internal Medicine - Division of Nephrology, University of Campinas, Campinas, Brazil, ²Department of Internal Medicine, University of Campinas, Campinas, Brazil, ³Department of Internal Medicine - Division of Infectious Diseases, University of Campinas, Campinas, Brazil, ⁴Surgery Department, University of Campinas, Campinas, Brazil
*Purpose: Yellow fever (YF) is a viral hemorrhagic disease transmitted by mosquitos, with variable clinical disease manifestations from a mild, undifferentiated febrile illness to severe…
2019 American Transplant Congress
Anti-HLA IgM Antibodies Are Reduced in Highly-HLA Sensitized Patients Transplanted after Imlifidase (IdeS) Treatment
X. Zhang¹, S. Jordan²
¹HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA
*Purpose: Immunoglobulin-degrading enzyme from Streptococcus pyogenes (IdeS, Imlifidase) has been used to reduce antibody levels to promote transplant of highly sensitized patients. In vitro experiments…